降钙素原测定在慢性阻塞性肺疾病急性加重期的临床意义

doi:10.3969/j.issn.1673-8640.2016.02.003

摘要/Abstract

摘要：

目的探讨降钙素原（PCT）在慢性阻塞性肺疾病急性加重期（AECOPD）病程中的临床意义。方法以48例痰菌培养阳性AECOPD患者为细菌感染组,48例痰菌培养阴性AECOPD患者为非细菌感染组,2个组分别检测PCT,细菌感染组在治疗后3、5 及7 d分别再检测1次PCT。结果细菌感染组PCT水平明显高于非细菌感染组（P<0.01）;细菌感染组治疗后3、5及7 d PCT浓度均明显持续下降,与治疗前差异均有统计学意义（P<0.01）;细菌感染组PCT在治疗后3 d就显示与治疗前有显著差异（P<0.01）,红细胞沉降率（ESR）、白细胞（WBC）计数、中性粒细胞计数（NC）等指标则在治疗后5 d才显著下降;细菌感染组有2例患者PCT水平持续增高,治疗无效,死亡,非细菌感染组患者均好转出院。结论 PCT是反映AECOPD患者肺部感染的敏感指标,也是反映AECOPD患者感染细菌是否被清除的最常用指标,可敏感地反映AECOPD患者治疗过程中炎症程度的变化,较好地考核抗菌治疗效果。

关键词: 降钙素原, 慢性阻塞性肺疾病, 急性加重期, 临床意义

Abstract:

Objective To investigate the clinical significance of procalcitonin （PCT） in acute exacerbation of chronic obstructive pulmonary disease （AECOPD）. Methods A total of 48 sputum culture positive patients with AECOPD were enrolled as bacterial infection group,and 48 sputum culture negative patients with AECOPD were enrolled as non-bacterial infection group. The PCT was determined,and PCT was determined again in bacterial infection group after treatment for 3,5 and 7 d. Results The level of PCT in bacterial infection group was significantly higher than that in non-bacterial infection group （P<0.01）. In bacterial infection group after treatment for 3,5 and 7 d,PCT levels decreased significantly with statistical significance compared with that before treatment（P<0.01）. The bacterial infection group after treatment for 3 d showed significant difference for PCT compared with that before treatment （P<0.01）. Erythrocyte sedimentation rate（ESR）,white blood cell（WBC）,neutrophil count（NC）and other indicators decreased significantly after treatment for 5 d . In bacterial infection group,2 patients had a continuous increasing of PCT and then died,and non-bacterial infection group all cured. Conclusions PCT is a sensitive index for pulmonary infection in patients with AECOPD,and it also reflects whether infection bacterium is removed or not. It is sensitive to reflect the changes of inflammation degrees and the effect of antimicrobial treatment in the treatment of patients with AECOPD .

Key words: Procalcitonin, Chronic obstructive pulmonary disease, Acute exacerbation, Clinical significance

中图分类号:

R446.62

王永, 傅士靖, 陈如健, 吕伟. 降钙素原测定在慢性阻塞性肺疾病急性加重期的临床意义[J]. 检验医学, 2016, 31(2): 91-94.

WANG Yong, FU Shijing, CHEN Rujian, LÜ Wei. Clinical significance of procalcitonin determination in acute exacerbation of chronic obstructive pulmonary disease[J]. Laboratory Medicine, 2016, 31(2): 91-94.

图/表 2

参考文献 14

[1]	ROTHBERG MB, PEKOW PS, LAHTI M, et al.Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease[J]. JAMA,2010,303(20):2035-2042.
[2]	SETHI S.Molecular diagnosis of respiratory tract infection in acute exacerbations of chronic obstructive pulmonary disease[J]. Clin Infect Dis,2011,52(Suppl 4):S290-S295.
[3]	BOIXEDA R, RABELLA N, SAUCA G, et al.Microbiological study of patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) and the usefulness of analytical and clinical parameters in its identification (VIRAE study)[J]. Int J Chron Obstruct Pulmon Dis,2012,7:327-335.
[4]	ALBRICH WC, DUSEMUND F, BUCHER B, et al.Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in "real life": an international, multicenter poststudy survey (ProREAL)[J]. Arch Intern Med,2012,172(9):715-722.
[5]	朱国民. 降钙素原与C 反应蛋白联合检测在慢性阻塞性肺疾病急性加重期的临床价值[J]. 检验医学,2014,29(12):1246-1247.
[6]	慕月晶,王伟佳,严海忠,等. PCT 检测在全身和局部细菌感染诊断中的临床应用[J]. 检验医学,2015,30(1):17-20.
[7]	HUR M, MOON HW, YUN YM, et al.Comparison of diagnostic utility between procalcitonin and C-reactive protein for the patients with blood culture-positive sepsis[J]. Korean J Lab Med,2009,29(6):529-535.
[8]	LEE JY, HWANG SJ, SHIM JW, et al.Clinical significance of serum procalcitonin in patients with community-acquired lobar pneumonia[J]. Korean J Lab Med,2010,30(4):406-413.
[9]	LACOMA A, PRAT C, ANDREO F, et al.Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis, 2011, 6: 157-169.
[10]	SCHUETZ P, CHRIST-CRAIN M, THOMANN R, et al.Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial[J]. JAMA, 2009, 302(10): 1059-1066.
[11]	DANIELS JM, SCHOORL M, SNIJDERS D, et al.Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD[J]. Chest, 2010, 138(5): 1108-1115.
[12]	EL MOUSSAOUI R, ROEDE BM, SPEELMAN P, et al.Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies[J]. Thorax, 2008, 63(5): 415-422.
[13]	EL-SOLH AA, VORA H, KNIGHT PR 3RD, et al. Diagnostic use of serum procalcitonin levels in pulmonary aspiration syndromes[J]. Crit Care Med, 2011, 39(6): 1251-1256.
[14]	FALSEY AR, BECKER KL, SWINBURNE AJ, et al.Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note[J]. Int J Chron Obstruct Pulmon Dis, 2012, 7: 127-135.

组别	例数	ESR（mm/h）	WBC计数（×10⁹/L）	NC （×10⁹/L）	PCT（ng/mL）
细菌感染组	48	23.4±12.0^*	11.76±2.74^*	11.26±2.54^*	0.365±0.129^*
非细菌感染组	48	11.9±4.3	6.41±1.44	4.42±1.09	0.132±0.056

组别	例数	ESR（mm/h）	WBC计数（×10⁹/L）	NC （×10⁹/L）	PCT（ng/mL）
细菌感染组	48	23.4±12.0^*	11.76±2.74^*	11.26±2.54^*	0.365±0.129^*
非细菌感染组	48	11.9±4.3	6.41±1.44	4.42±1.09	0.132±0.056

组别	例数	ESR（mm/h）	WBC计数（×10⁹/L）	NC （×10⁹/L）	PCT（ng/mL）
治疗前	48	23.4±12.0	11.76±2.74	11.26±2.54	0.365±0.129
治疗后3 d	48	21.5±10.3	11.16±2.41	10.46±2.49	0.290±0.117^**
治疗后5 d	48	18.3±9.1^*	9.48±2.44^**#	8.03±2.02^**#	0.215±0.100^**#
治疗后7 d	48	14.0±5.7^**#△	7.95±2.16^**#△△	6.53±1.52^**#△△	0.172±0.063^**#△

组别	例数	ESR（mm/h）	WBC计数（×10⁹/L）	NC （×10⁹/L）	PCT（ng/mL）
治疗前	48	23.4±12.0	11.76±2.74	11.26±2.54	0.365±0.129
治疗后3 d	48	21.5±10.3	11.16±2.41	10.46±2.49	0.290±0.117^**
治疗后5 d	48	18.3±9.1^*	9.48±2.44^**#	8.03±2.02^**#	0.215±0.100^**#
治疗后7 d	48	14.0±5.7^**#△	7.95±2.16^**#△△	6.53±1.52^**#△△	0.172±0.063^**#△

[1]	李莉, 孙海燕, 李媛睿, 窦敏, 汤文, 蒋黎敏, 沈立松. 先天性心脏病患儿围手术期NT-proBNP、 PCT变化及其临床意义[J]. 检验医学, 2023, 38(6): 524-531.
[2]	马大文, 王宏俊, 胡莎莎. NLR、PLR联合MPV预测老年慢性阻塞性肺疾病患者急性加重期近期预后不良的价值[J]. 检验医学, 2022, 37(9): 850-854.
[3]	翟莎娜, 孙清海, 余永武, 叶芳, 刘茂东. 万古霉素联合美罗培南对PDRP患者疗效及血清TNF-α、PCT、IL-6水平和腹膜液WBC计数的影响[J]. 检验医学, 2022, 37(4): 360-364.
[4]	顾峰, 吴艳芬, 赵歆晖, 侯照远, 王志宏, 齐华林. 降钙素原水平与维持性血液透析患者全因死亡的关系[J]. 检验医学, 2022, 37(2): 134-140.
[5]	张颖, 刘慧玲. COPD合并感染患者血清甲状腺激素水平变化及其与低T₃综合征的关系[J]. 检验医学, 2022, 37(11): 1062-1065.
[6]	何学联, 何子翼, 刘月阳, 余炎芝, 张思颖. 基于外周血炎症指标的列线图模型早期诊断新生儿败血症的价值[J]. 检验医学, 2022, 37(10): 921-927.
[7]	王晓清, 彭雪梅, 兰美锋, 潘敏. MCP-1联合CREWS在AECOPD患者不良预后评估中的价值[J]. 检验医学, 2022, 37(10): 934-938.
[8]	李亚周, 马炜, 刘云, 万玉香, 黄晓春, 秦琴. 多指标联合检测在血流感染早期诊断中的价值[J]. 检验医学, 2021, 36(8): 847-850.
[9]	陈金来, 张菊英, 秦红, 赵津辉. 血清D-二聚体水平对预测老年慢性阻塞性肺疾病患者预后的价值[J]. 检验医学, 2021, 36(3): 309-312.
[10]	朱传新, 周玉平, 何艳, 周琴. NLR、CRP、PCT、DD、NT-proBNP在重症COVID-19中的诊断价值[J]. 检验医学, 2021, 36(2): 190-193.
[11]	潘锡龙, 徐志远, 谢锋, 李丹. 不同脓毒症诊断标准中降钙素原的临床意义[J]. 检验医学, 2021, 36(12): 1215-1218.
[12]	武静, 于瑞杰. SAA、PCT、PA和CRP在儿童感染性疾病中的价值[J]. 检验医学, 2021, 36(11): 1190-1191.
[13]	朱传新, 周玉平, 周琴, 周桂凤. NLR、PCT、CRP联合检测对早期COVID-19的诊断价值[J]. 检验医学, 2021, 36(1): 53-56.
[14]	赵明海, 李欣, 魏东, 罗敏, 张雅洁, 杨懿祺, 郑磊. 干热法灭活对新型冠状病毒肺炎相关炎症指标检测的影响[J]. 检验医学, 2020, 35(9): 924-927.
[15]	黄隽敏, 庄须翠, 秋爽. 慢性阻塞性肺疾病急性加重患者下呼吸道病原菌菌种分布及耐药性分析[J]. 检验医学, 2020, 35(8): 771-774.